Novavax, Inc. (NASDAQ:NVAX) Receives Average Recommendation of “Hold” from Analysts

Novavax, Inc. (NASDAQ:NVAXGet Free Report) has been given a consensus recommendation of “Hold” by the five analysts that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $17.50.

Several equities analysts have recently weighed in on NVAX shares. HC Wainwright reaffirmed a “buy” rating and set a $19.00 target price on shares of Novavax in a report on Monday, May 13th. TD Cowen boosted their price target on shares of Novavax from $5.00 to $10.00 and gave the stock a “hold” rating in a report on Monday, May 13th. B. Riley boosted their price target on shares of Novavax from $11.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, May 23rd. Bank of America raised shares of Novavax from an “underperform” rating to a “neutral” rating and boosted their price target for the stock from $4.00 to $12.00 in a report on Friday, May 10th. Finally, JPMorgan Chase & Co. raised shares of Novavax from an “underweight” rating to a “neutral” rating in a report on Friday, May 10th.

View Our Latest Report on Novavax

Novavax Price Performance

NASDAQ:NVAX opened at $19.56 on Friday. The firm has a market cap of $2.75 billion, a price-to-earnings ratio of -6.17, a price-to-earnings-growth ratio of 1.04 and a beta of 1.96. The company has a 50 day moving average price of $8.71 and a 200-day moving average price of $6.20. Novavax has a 1-year low of $3.53 and a 1-year high of $23.86.

Novavax (NASDAQ:NVAXGet Free Report) last posted its earnings results on Friday, May 10th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($1.04) by ($0.01). The firm had revenue of $93.90 million for the quarter, compared to analysts’ expectations of $71.32 million. Novavax’s quarterly revenue was up 15.9% on a year-over-year basis. During the same period last year, the business posted ($3.41) earnings per share. On average, sell-side analysts anticipate that Novavax will post 0.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Novavax news, insider Filip Dubovsky sold 47,312 shares of Novavax stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $13.90, for a total transaction of $657,636.80. Following the sale, the insider now owns 38,953 shares of the company’s stock, valued at approximately $541,446.70. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Novavax

Several institutional investors and hedge funds have recently added to or reduced their stakes in NVAX. Swedbank AB acquired a new position in shares of Novavax during the 1st quarter valued at about $26,000. Hodges Capital Management Inc. acquired a new position in shares of Novavax during the 3rd quarter valued at about $72,000. Herr Investment Group LLC acquired a new position in shares of Novavax during the 1st quarter valued at about $48,000. Nomura Holdings Inc. acquired a new position in shares of Novavax during the 3rd quarter valued at about $74,000. Finally, Alpine Global Management LLC acquired a new position in shares of Novavax during the 1st quarter valued at about $49,000. Institutional investors and hedge funds own 53.04% of the company’s stock.

About Novavax

(Get Free Report

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.

Further Reading

Analyst Recommendations for Novavax (NASDAQ:NVAX)

Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.